 | • レポートコード：MRC2Q12-16746 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、細胞＆遺伝子治療CDMOのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 細胞＆遺伝子治療CDMOのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 細胞＆遺伝子治療CDMOの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 細胞＆遺伝子治療CDMOのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの細胞＆遺伝子治療CDMOの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の細胞＆遺伝子治療CDMOの売上および2028年までの予測に焦点を当てています。 細胞＆遺伝子治療CDMOのグローバル主要企業には、Catalent、Lonza、Charles River、The Discovery Labs、BIOCENTRIQ、FUJIFILM Diosynth Biotechnologies、Exothera、WuXi AppTec、Pharmaron、OBiO、Cell Therapies、AGC Biologics、Cytiva、Helixmith、ThermoGenesis、Anemocyte、Thermo Fisher Scientific、CBM、Bio Elpida、Genezen、CCRM、RoslinCT、GenScript ProBio、Oxford BioMedica、Porton Pharma Solutionsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 細胞＆遺伝子治療CDMO市場は、タイプとアプリケーションによって区分されます。世界の細胞＆遺伝子治療CDMO市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 細胞治療、ウイルスベクター、プラスミド 【アプリケーション別セグメント】 商業、学術研究、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 細胞＆遺伝子治療CDMO製品概要 - タイプ別市場（細胞治療、ウイルスベクター、プラスミド） - アプリケーション別市場（商業、学術研究、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の細胞＆遺伝子治療CDMO販売量予測2017-2028 - 世界の細胞＆遺伝子治療CDMO売上予測2017-2028 - 細胞＆遺伝子治療CDMOの地域別販売量 - 細胞＆遺伝子治療CDMOの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別細胞＆遺伝子治療CDMO販売量 - 主要メーカー別細胞＆遺伝子治療CDMO売上 - 主要メーカー別細胞＆遺伝子治療CDMO価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（細胞治療、ウイルスベクター、プラスミド） - 細胞＆遺伝子治療CDMOのタイプ別販売量 - 細胞＆遺伝子治療CDMOのタイプ別売上 - 細胞＆遺伝子治療CDMOのタイプ別価格 ・アプリケーション別市場規模（商業、学術研究、その他） - 細胞＆遺伝子治療CDMOのアプリケーション別販売量 - 細胞＆遺伝子治療CDMOのアプリケーション別売上 - 細胞＆遺伝子治療CDMOのアプリケーション別価格 ・北米市場 - 北米の細胞＆遺伝子治療CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の細胞＆遺伝子治療CDMO市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの細胞＆遺伝子治療CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の細胞＆遺伝子治療CDMO市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の細胞＆遺伝子治療CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の細胞＆遺伝子治療CDMO市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の細胞＆遺伝子治療CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の細胞＆遺伝子治療CDMO市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの細胞＆遺伝子治療CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の細胞＆遺伝子治療CDMO市場規模（トルコ、サウジアラビア） ・企業情報 Catalent、Lonza、Charles River、The Discovery Labs、BIOCENTRIQ、FUJIFILM Diosynth Biotechnologies、Exothera、WuXi AppTec、Pharmaron、OBiO、Cell Therapies、AGC Biologics、Cytiva、Helixmith、ThermoGenesis、Anemocyte、Thermo Fisher Scientific、CBM、Bio Elpida、Genezen、CCRM、RoslinCT、GenScript ProBio、Oxford BioMedica、Porton Pharma Solutions ・産業チェーン及び販売チャネル分析 - 細胞＆遺伝子治療CDMOの産業チェーン分析 - 細胞＆遺伝子治療CDMOの原材料 - 細胞＆遺伝子治療CDMOの生産プロセス - 細胞＆遺伝子治療CDMOの販売及びマーケティング - 細胞＆遺伝子治療CDMOの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 細胞＆遺伝子治療CDMOの産業動向 - 細胞＆遺伝子治療CDMOのマーケットドライバー - 細胞＆遺伝子治療CDMOの課題 - 細胞＆遺伝子治療CDMOの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Cellular and Gene Therapy CDMO estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Cellular and Gene Therapy CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Cellular and Gene Therapy CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Cellular and Gene Therapy CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Cellular and Gene Therapy CDMO include Catalent, Lonza, Charles River, The Discovery Labs, BIOCENTRIQ, FUJIFILM Diosynth Biotechnologies, Exothera, WuXi AppTec and Pharmaron, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Cellular and Gene Therapy CDMO companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Cellular and Gene Therapy CDMO market. Further, it explains the major drivers and regional dynamics of the global Cellular and Gene Therapy CDMO market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Catalent
Lonza
Charles River
The Discovery Labs
BIOCENTRIQ
FUJIFILM Diosynth Biotechnologies
Exothera
WuXi AppTec
Pharmaron
OBiO
Cell Therapies
AGC Biologics
Cytiva
Helixmith
ThermoGenesis
Anemocyte
Thermo Fisher Scientific
CBM
Bio Elpida
Genezen
CCRM
RoslinCT
GenScript ProBio
Oxford BioMedica
Porton Pharma Solutions
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Cellular and Gene Therapy CDMO Segment by Type
Cell Therapy
Viral Vectors
Plasmid
Cellular and Gene Therapy CDMO Segment by Application
Commercial
Academic Research
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Cellular and Gene Therapy CDMO market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Cellular and Gene Therapy CDMO market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Cellular and Gene Therapy CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Cellular and Gene Therapy CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cellular and Gene Therapy CDMO revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Cellular and Gene Therapy CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Cellular and Gene Therapy CDMO revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Catalent, Lonza, Charles River, The Discovery Labs, BIOCENTRIQ, FUJIFILM Diosynth Biotechnologies, Exothera, WuXi AppTec and Pharmaron, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Cellular and Gene Therapy CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cellular and Gene Therapy CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cellular and Gene Therapy CDMO revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cellular and Gene Therapy CDMO Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Cell Therapy
1.2.3 Viral Vectors
1.2.4 Plasmid
1.3 Market by Application
1.3.1 Global Cellular and Gene Therapy CDMO Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Commercial
1.3.3 Academic Research
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cellular and Gene Therapy CDMO Market Perspective (2017-2028)
2.2 Cellular and Gene Therapy CDMO Growth Trends by Region
2.2.1 Cellular and Gene Therapy CDMO Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Cellular and Gene Therapy CDMO Historic Market Size by Region (2017-2022)
2.2.3 Cellular and Gene Therapy CDMO Forecasted Market Size by Region (2023-2028)
2.3 Cellular and Gene Therapy CDMO Market Dynamics
2.3.1 Cellular and Gene Therapy CDMO Industry Trends
2.3.2 Cellular and Gene Therapy CDMO Market Drivers
2.3.3 Cellular and Gene Therapy CDMO Market Challenges
2.3.4 Cellular and Gene Therapy CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cellular and Gene Therapy CDMO Players by Revenue
3.1.1 Global Top Cellular and Gene Therapy CDMO Players by Revenue (2017-2022)
3.1.2 Global Cellular and Gene Therapy CDMO Revenue Market Share by Players (2017-2022)
3.2 Global Cellular and Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cellular and Gene Therapy CDMO Revenue
3.4 Global Cellular and Gene Therapy CDMO Market Concentration Ratio
3.4.1 Global Cellular and Gene Therapy CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cellular and Gene Therapy CDMO Revenue in 2021
3.5 Cellular and Gene Therapy CDMO Key Players Head office and Area Served
3.6 Key Players Cellular and Gene Therapy CDMO Product Solution and Service
3.7 Date of Enter into Cellular and Gene Therapy CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cellular and Gene Therapy CDMO Breakdown Data by Type
4.1 Global Cellular and Gene Therapy CDMO Historic Market Size by Type (2017-2022)
4.2 Global Cellular and Gene Therapy CDMO Forecasted Market Size by Type (2023-2028)
5 Cellular and Gene Therapy CDMO Breakdown Data by Application
5.1 Global Cellular and Gene Therapy CDMO Historic Market Size by Application (2017-2022)
5.2 Global Cellular and Gene Therapy CDMO Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Cellular and Gene Therapy CDMO Market Size (2017-2028)
6.2 North America Cellular and Gene Therapy CDMO Market Size by Type
6.2.1 North America Cellular and Gene Therapy CDMO Market Size by Type (2017-2022)
6.2.2 North America Cellular and Gene Therapy CDMO Market Size by Type (2023-2028)
6.2.3 North America Cellular and Gene Therapy CDMO Market Share by Type (2017-2028)
6.3 North America Cellular and Gene Therapy CDMO Market Size by Application
6.3.1 North America Cellular and Gene Therapy CDMO Market Size by Application (2017-2022)
6.3.2 North America Cellular and Gene Therapy CDMO Market Size by Application (2023-2028)
6.3.3 North America Cellular and Gene Therapy CDMO Market Share by Application (2017-2028)
6.4 North America Cellular and Gene Therapy CDMO Market Size by Country
6.4.1 North America Cellular and Gene Therapy CDMO Market Size by Country (2017-2022)
6.4.2 North America Cellular and Gene Therapy CDMO Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Cellular and Gene Therapy CDMO Market Size (2017-2028)
7.2 Europe Cellular and Gene Therapy CDMO Market Size by Type
7.2.1 Europe Cellular and Gene Therapy CDMO Market Size by Type (2017-2022)
7.2.2 Europe Cellular and Gene Therapy CDMO Market Size by Type (2023-2028)
7.2.3 Europe Cellular and Gene Therapy CDMO Market Share by Type (2017-2028)
7.3 Europe Cellular and Gene Therapy CDMO Market Size by Application
7.3.1 Europe Cellular and Gene Therapy CDMO Market Size by Application (2017-2022)
7.3.2 Europe Cellular and Gene Therapy CDMO Market Size by Application (2023-2028)
7.3.3 Europe Cellular and Gene Therapy CDMO Market Share by Application (2017-2028)
7.4 Europe Cellular and Gene Therapy CDMO Market Size by Country
7.4.1 Europe Cellular and Gene Therapy CDMO Market Size by Country (2017-2022)
7.4.2 Europe Cellular and Gene Therapy CDMO Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cellular and Gene Therapy CDMO Market Size (2017-2028)
8.2 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Type
8.2.1 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Cellular and Gene Therapy CDMO Market Share by Type (2017-2028)
8.3 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Application
8.3.1 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Cellular and Gene Therapy CDMO Market Share by Application (2017-2028)
8.4 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Region
8.4.1 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Cellular and Gene Therapy CDMO Market Size (2017-2028)
9.2 Latin America Cellular and Gene Therapy CDMO Market Size by Type
9.2.1 Latin America Cellular and Gene Therapy CDMO Market Size by Type (2017-2022)
9.2.2 Latin America Cellular and Gene Therapy CDMO Market Size by Type (2023-2028)
9.2.3 Latin America Cellular and Gene Therapy CDMO Market Share by Type (2017-2028)
9.3 Latin America Cellular and Gene Therapy CDMO Market Size by Application
9.3.1 Latin America Cellular and Gene Therapy CDMO Market Size by Application (2017-2022)
9.3.2 Latin America Cellular and Gene Therapy CDMO Market Size by Application (2023-2028)
9.3.3 Latin America Cellular and Gene Therapy CDMO Market Share by Application (2017-2028)
9.4 Latin America Cellular and Gene Therapy CDMO Market Size by Country
9.4.1 Latin America Cellular and Gene Therapy CDMO Market Size by Country (2017-2022)
9.4.2 Latin America Cellular and Gene Therapy CDMO Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cellular and Gene Therapy CDMO Market Size (2017-2028)
10.2 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Type
10.2.1 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Cellular and Gene Therapy CDMO Market Share by Type (2017-2028)
10.3 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Application
10.3.1 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Cellular and Gene Therapy CDMO Market Share by Application (2017-2028)
10.4 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Country
10.4.1 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Catalent
11.1.1 Catalent Company Details
11.1.2 Catalent Business Overview
11.1.3 Catalent Cellular and Gene Therapy CDMO Introduction
11.1.4 Catalent Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.1.5 Catalent Recent Developments
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Cellular and Gene Therapy CDMO Introduction
11.2.4 Lonza Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.2.5 Lonza Recent Developments
11.3 Charles River
11.3.1 Charles River Company Details
11.3.2 Charles River Business Overview
11.3.3 Charles River Cellular and Gene Therapy CDMO Introduction
11.3.4 Charles River Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.3.5 Charles River Recent Developments
11.4 The Discovery Labs
11.4.1 The Discovery Labs Company Details
11.4.2 The Discovery Labs Business Overview
11.4.3 The Discovery Labs Cellular and Gene Therapy CDMO Introduction
11.4.4 The Discovery Labs Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.4.5 The Discovery Labs Recent Developments
11.5 BIOCENTRIQ
11.5.1 BIOCENTRIQ Company Details
11.5.2 BIOCENTRIQ Business Overview
11.5.3 BIOCENTRIQ Cellular and Gene Therapy CDMO Introduction
11.5.4 BIOCENTRIQ Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.5.5 BIOCENTRIQ Recent Developments
11.6 FUJIFILM Diosynth Biotechnologies
11.6.1 FUJIFILM Diosynth Biotechnologies Company Details
11.6.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.6.3 FUJIFILM Diosynth Biotechnologies Cellular and Gene Therapy CDMO Introduction
11.6.4 FUJIFILM Diosynth Biotechnologies Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.6.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.7 Exothera
11.7.1 Exothera Company Details
11.7.2 Exothera Business Overview
11.7.3 Exothera Cellular and Gene Therapy CDMO Introduction
11.7.4 Exothera Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.7.5 Exothera Recent Developments
11.8 WuXi AppTec
11.8.1 WuXi AppTec Company Details
11.8.2 WuXi AppTec Business Overview
11.8.3 WuXi AppTec Cellular and Gene Therapy CDMO Introduction
11.8.4 WuXi AppTec Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.8.5 WuXi AppTec Recent Developments
11.9 Pharmaron
11.9.1 Pharmaron Company Details
11.9.2 Pharmaron Business Overview
11.9.3 Pharmaron Cellular and Gene Therapy CDMO Introduction
11.9.4 Pharmaron Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.9.5 Pharmaron Recent Developments
11.10 OBiO
11.10.1 OBiO Company Details
11.10.2 OBiO Business Overview
11.10.3 OBiO Cellular and Gene Therapy CDMO Introduction
11.10.4 OBiO Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.10.5 OBiO Recent Developments
11.11 Cell Therapies
11.11.1 Cell Therapies Company Details
11.11.2 Cell Therapies Business Overview
11.11.3 Cell Therapies Cellular and Gene Therapy CDMO Introduction
11.11.4 Cell Therapies Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.11.5 Cell Therapies Recent Developments
11.12 AGC Biologics
11.12.1 AGC Biologics Company Details
11.12.2 AGC Biologics Business Overview
11.12.3 AGC Biologics Cellular and Gene Therapy CDMO Introduction
11.12.4 AGC Biologics Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.12.5 AGC Biologics Recent Developments
11.13 Cytiva
11.13.1 Cytiva Company Details
11.13.2 Cytiva Business Overview
11.13.3 Cytiva Cellular and Gene Therapy CDMO Introduction
11.13.4 Cytiva Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.13.5 Cytiva Recent Developments
11.14 Helixmith
11.14.1 Helixmith Company Details
11.14.2 Helixmith Business Overview
11.14.3 Helixmith Cellular and Gene Therapy CDMO Introduction
11.14.4 Helixmith Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.14.5 Helixmith Recent Developments
11.15 ThermoGenesis
11.15.1 ThermoGenesis Company Details
11.15.2 ThermoGenesis Business Overview
11.15.3 ThermoGenesis Cellular and Gene Therapy CDMO Introduction
11.15.4 ThermoGenesis Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.15.5 ThermoGenesis Recent Developments
11.16 Anemocyte
11.16.1 Anemocyte Company Details
11.16.2 Anemocyte Business Overview
11.16.3 Anemocyte Cellular and Gene Therapy CDMO Introduction
11.16.4 Anemocyte Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.16.5 Anemocyte Recent Developments
11.17 Thermo Fisher Scientific
11.17.1 Thermo Fisher Scientific Company Details
11.17.2 Thermo Fisher Scientific Business Overview
11.17.3 Thermo Fisher Scientific Cellular and Gene Therapy CDMO Introduction
11.17.4 Thermo Fisher Scientific Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.17.5 Thermo Fisher Scientific Recent Developments
11.18 CBM
11.18.1 CBM Company Details
11.18.2 CBM Business Overview
11.18.3 CBM Cellular and Gene Therapy CDMO Introduction
11.18.4 CBM Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.18.5 CBM Recent Developments
11.19 Bio Elpida
11.19.1 Bio Elpida Company Details
11.19.2 Bio Elpida Business Overview
11.19.3 Bio Elpida Cellular and Gene Therapy CDMO Introduction
11.19.4 Bio Elpida Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.19.5 Bio Elpida Recent Developments
11.20 Genezen
11.20.1 Genezen Company Details
11.20.2 Genezen Business Overview
11.20.3 Genezen Cellular and Gene Therapy CDMO Introduction
11.20.4 Genezen Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.20.5 Genezen Recent Developments
11.21 CCRM
11.21.1 CCRM Company Details
11.21.2 CCRM Business Overview
11.21.3 CCRM Cellular and Gene Therapy CDMO Introduction
11.21.4 CCRM Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.21.5 CCRM Recent Developments
11.22 RoslinCT
11.22.1 RoslinCT Company Details
11.22.2 RoslinCT Business Overview
11.22.3 RoslinCT Cellular and Gene Therapy CDMO Introduction
11.22.4 RoslinCT Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.22.5 RoslinCT Recent Developments
11.23 GenScript ProBio
11.23.1 GenScript ProBio Company Details
11.23.2 GenScript ProBio Business Overview
11.23.3 GenScript ProBio Cellular and Gene Therapy CDMO Introduction
11.23.4 GenScript ProBio Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.23.5 GenScript ProBio Recent Developments
11.24 Oxford BioMedica
11.24.1 Oxford BioMedica Company Details
11.24.2 Oxford BioMedica Business Overview
11.24.3 Oxford BioMedica Cellular and Gene Therapy CDMO Introduction
11.24.4 Oxford BioMedica Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.24.5 Oxford BioMedica Recent Developments
11.25 Porton Pharma Solutions
11.25.1 Porton Pharma Solutions Company Details
11.25.2 Porton Pharma Solutions Business Overview
11.25.3 Porton Pharma Solutions Cellular and Gene Therapy CDMO Introduction
11.25.4 Porton Pharma Solutions Revenue in Cellular and Gene Therapy CDMO Business (2017-2022)
11.25.5 Porton Pharma Solutions Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer